|
GB1142508A
(en)
*
|
1966-04-27 |
1969-02-12 |
Whitefin Holding Sa |
Pyrrole derivatives
|
|
GB1154744A
(en)
*
|
1966-05-17 |
1969-06-11 |
Whitefin Holding Sa |
Disubstituted Aminoethanols
|
|
CZ20002669A3
(cs)
|
1998-01-23 |
2001-11-14 |
National Jewish Medical And Research Center |
Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
|
|
US7842470B2
(en)
|
2001-10-09 |
2010-11-30 |
Oregon Health & Science University |
Method for pharmacoperones correction of GnRHR mutant protein misfolding
|
|
US20060148767A1
(en)
|
2001-12-06 |
2006-07-06 |
George Cioca |
Use of acyl salicylates as heat shock inducers
|
|
EP1682504B1
(en)
|
2003-11-12 |
2012-12-26 |
Amicus Therapeutics Inc. |
Hydroxy piperidine derivatives to treat gaucher disease
|
|
EP2932982B1
(en)
|
2005-05-17 |
2018-10-03 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
CN101541172A
(zh)
|
2005-06-08 |
2009-09-23 |
阿米库斯治疗学公司 |
溶酶体酶编码基因突变相关的cns紊乱的治疗
|
|
US20070207992A1
(en)
|
2006-02-21 |
2007-09-06 |
Board Of Trustees Of Michigan State University |
Geldanamycin derivatives and method of use thereof
|
|
WO2007131034A1
(en)
|
2006-05-03 |
2007-11-15 |
The Regents Of The University Of Michigan |
Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
|
|
ES2573498T3
(es)
|
2006-05-16 |
2016-06-08 |
Amicus Therapeutics, Inc. |
Opciones de tratamiento para la enfermedad de Fabry
|
|
PT1860101E
(pt)
|
2006-05-24 |
2011-07-12 |
Amicus Therapeutics Inc |
Sal de tartrato da isofagomina e métodos de uso
|
|
JP5303458B2
(ja)
|
2006-06-23 |
2013-10-02 |
アミークス セラピューティックス インコーポレイテッド |
β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
|
|
US8143269B2
(en)
*
|
2008-10-03 |
2012-03-27 |
Calcimedica, Inc. |
Inhibitors of store operated calcium release
|
|
MX336731B
(es)
*
|
2010-01-28 |
2016-01-28 |
Harvard College |
Composiciones y metodos para potenciar la actividad de proteasoma.
|
|
WO2011127333A2
(en)
*
|
2010-04-09 |
2011-10-13 |
University Of Louisville Research Foundation, Inc. |
Compounds for treating disease, for administering, and for pharmaceutical compositions
|
|
WO2012078902A2
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators
|
|
WO2012078909A1
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Thiazolpyrimidine proteostasis regulators
|
|
WO2012154880A1
(en)
|
2011-05-09 |
2012-11-15 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
|
|
DK2707101T3
(da)
*
|
2011-05-12 |
2019-05-13 |
Proteostasis Therapeutics Inc |
Proteostaseregulatorer
|
|
WO2013112699A2
(en)
|
2012-01-25 |
2013-08-01 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
CA2861464C
(en)
|
2012-01-25 |
2018-03-06 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating tricyclic compounds
|
|
US9849135B2
(en)
*
|
2013-01-25 |
2017-12-26 |
President And Fellows Of Harvard College |
USP14 inhibitors for treating or preventing viral infections
|
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
|
WO2015073528A1
(en)
|
2013-11-12 |
2015-05-21 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
US9745292B2
(en)
|
2014-03-13 |
2017-08-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
|
WO2015138909A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
EP3157917B1
(en)
|
2014-06-19 |
2020-03-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
CN104478780B
(zh)
*
|
2014-11-17 |
2017-04-19 |
华东师范大学 |
酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
|
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10392378B2
(en)
|
2014-12-23 |
2019-08-27 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10344023B2
(en)
|
2014-12-23 |
2019-07-09 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US10548878B2
(en)
|
2015-07-24 |
2020-02-04 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods of increasing CFTR activity
|
|
US20190022071A1
(en)
|
2015-08-31 |
2019-01-24 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
BR112018007021B1
(pt)
|
2015-10-06 |
2024-01-09 |
Proteostasis Therapeutics, Inc |
Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
|
|
US20180369209A1
(en)
|
2015-12-22 |
2018-12-27 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
MA43775A
(fr)
|
2016-04-07 |
2021-05-05 |
Proteostasis Therapeutics Inc |
Analogues du ivacaftor conentant des atomes de silicium
|
|
US20190154661A1
(en)
|
2016-05-09 |
2019-05-23 |
Proteostasis Therapeutics, Inc. |
Methods of identifying cftr modulators
|
|
MA45397A
(fr)
|
2016-06-21 |
2019-04-24 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
CA3041675A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
|
WO2018081378A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating cftr
|
|
AU2017348186A1
(en)
|
2016-10-26 |
2019-05-16 |
Proteostasis Therapeutics, Inc |
Pyridazine derivatives, compositions and methods for modulating CFTR
|
|
MA49061A
(fr)
|
2017-04-28 |
2021-04-21 |
Proteostasis Therapeutics Inc |
Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
|
|
AU2018346602B2
(en)
|
2017-10-06 |
2024-10-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods for increasing CFTR activity
|
|
CN112585130A
(zh)
*
|
2018-06-27 |
2021-03-30 |
蛋白质平衡治疗股份有限公司 |
蛋白酶体活性增强化合物
|